Overview

Angiotensin II Antagonist in Severe Sepsis

Status:
Unknown status

Trial end date:
2017-01-01

Target enrollment:
0

Participant gender:
All

Summary

The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Salerno

Collaborator:

Federico II University

Treatments:

Candesartan
Irbesartan
Olmesartan
Telmisartan

Criteria

Inclusion Criteria: adults within 12 hrs of recognition of severe sepsis, with Acute
Physiology and Chronic Health Evaluation (APACHE) II-predicted risk of mortality between
20% and 80% are eligible.

Exclusion Criteria:Patients already treated with ACE inhibitors or ARBs will be excluded.
Patients admitted in shock conditions (systolic blood pressure lower than 90 mmHg) will be
excluded. Patients with severe renal failure (serum creatinine of 2.0 mg/dL or dialysis)
will be excluded.